180 Life Sciences Reports Leadership/Compensation Changes

TL;DR

**180 Life Sciences just reported a leadership or compensation change on Jan 23, 2024, watch for details.**

AI Summary

180 Life Sciences Corp. filed an 8-K on January 29, 2024, reporting an event that occurred on January 23, 2024. This filing indicates a change in the company's leadership or compensatory arrangements, as detailed under Item 5.02. While the specific details of the departure, election, or appointment are not provided in this excerpt, such changes can signal strategic shifts or operational adjustments, which could impact investor confidence and the company's future direction.

Why It Matters

Changes in executive leadership or compensation can signal strategic shifts or financial health, directly influencing investor perception and the company's operational stability.

Risk Assessment

Risk Level: medium — Without specific details on the personnel changes or compensation arrangements, the impact on the company's stability and future performance is uncertain, posing a moderate risk.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the changes mentioned in Item 5.02 to understand their potential impact on the company's strategy and operations.

Key Players & Entities

• 180 Life Sciences Corp. (company) — the registrant filing the 8-K
• January 23, 2024 (date) — date of the earliest event reported
• January 29, 2024 (date) — date the 8-K was filed
• Item 5.02 (number) — SEC filing item for Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
• $100,000 — icer, whose total compensation exceeded $100,000, and (iii) if applicable, up to two add
• $10,000 — mount of such compensation is more than $10,000. No executive officer earned non-equity
• $390,000 — reed to pay Mr. Vu a starting salary of $390,000 per year. As of the date of this proxy
• $88.60 — common stock with an exercise price of $88.60 per share which were granted on Februar
• $79.00 — common stock with an exercise price of $79.00 per share which were granted on Decembe

Filing Documents

• ea192211-8k_180life.htm (8-K) — 50KB
• 0001213900-24-007176.txt ( ) — 266KB
• atnf-20240123.xsd (EX-101.SCH) — 4KB
• atnf-20240123_def.xml (EX-101.DEF) — 26KB
• atnf-20240123_lab.xml (EX-101.LAB) — 36KB
• atnf-20240123_pre.xml (EX-101.PRE) — 25KB
• ea192211-8k_180life_htm.xml (XML) — 6KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On January 23, 2024, the Board of Directors of 180 Life Sciences Corp. (the " Company ", " we " and " us "), determined that no bonuses would be granted to management for the years ended December 31, 2022 or 2023, and that no bonus amounts would be accrued for the year ended December 31, 2024. (f) On April 28, 2023, the Company filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission (the " Annual Report "). Pursuant to Instruction 1 to Item 402(n)(2)(iv) of Regulation S-K, the Company omitted from the Summary Executive Compensation Table included in the Annual Report, final bonus amounts to management with respect to the Company's fiscal year ended December 31, 2022 (the " 2022 Bonuses "), because the 2022 Bonuses had not yet been determined at the time the Annual Report was filed. In accordance with Item 5.02(f) of Form 8-K, the Company is providing a revised Summary Executive Compensation Table, which includes the 2022 Bonuses and revised total compensation figures for the Company's fiscal year ended December 31, 2022, below: Summary Executive Compensation Table The following table sets forth certain information concerning compensation earned by or paid to certain persons who we refer to as our " Named Executive Officers " for services provided for the fiscal years ended December 31, 2022 and 2021. Our Named Executive Officers include persons who (i) served as our principal executive officer or acted in a similar capacity during the years ended December 31, 2022 and 2021, (ii) were serving at fiscal year-end as our two most highly compensated executive officers, other than the principal executive officer, whose total compensation exceeded $100,000, and (iii) if applicable, up to two additional individuals for whom d

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 180 LIFE SCIENCES CORP. Date: January 29, 2024 By: /s/ James N. Woody, M.D., Ph.D. James N. Woody, M.D., Ph.D. Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR